Intellia Therapeutics Announces Third Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics Announces Third Quarter 2019 Financial Results

Intellia Therapeutics (NTLA) Tops Q3 EPS by 13c, Revenues Beat

October 31, 2019 7:46 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.49), $0.13 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10.62 million versus the consensus estimate of $9.43 million.

On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosisExpects to nominate its first T cell receptor-directed engineered cell therapy development candidate for the treatment of acute myeloid leukemia by the end of 2019Presented preclinical data including... More